Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Cybin Inc N.CYBN

Alternate Symbol(s):  CYBN

Cybin Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company creates psychedelic-based therapeutics to address the unmet need for treatment options for people who suffer from mental health conditions. Its N,N-dimethyltryptamine (DMT) and dDMT programs creates a dataset of systematic research on these psychedelic molecules. The Company is developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated dDMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. CYB003 moves to Phase III and CYB004 moves to Phase II. It has an intellectual property portfolio in the psychedelic drug development sector with over 30 patents granted and 160 patents pending. The Company operates in Canada, the United States, the United Kingdom, the Netherlands and Ireland.
๏ปฟ

NEO:CYBN - Post by User

<< Previous
Bullboard Posts
Next >>
Post by Jim1274on Dec 19, 2020 11:11am
224 Views
Post# 32146879

CYBIN ๐Ÿš€๐ŸŒ–๐Ÿฆพ

CYBIN ๐Ÿš€๐ŸŒ–๐ŸฆพLONDON, Dec. 17, 2020 /PRNewswire/ -- BRITAIN'S first investment fund dedicated solely to psychedelic healthcare has launched (17 December).

The fund, launched by Neo Kuma Ventures which has already attracted millions of pounds in investment, has no set cap and will continue to draw venture capital through the first half of 2021.
<< Previous
Bullboard Posts
Next >>